文献速递免疫规划

特应性皮炎小鼠模型中湿疹性牛痘的诱导、治疗与预防

Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models.
PubMed 文献 · Vaccine · 2017-06-20

研究建立特应性皮炎与湿疹性牛痘小鼠模型,模拟人类疾病严重程度,并评估西多福韦、抗病毒抗体及改良安卡拉痘苗病毒(MVA)疫苗接种的保护效果。

要点

  • 特应性皮炎小鼠经鼠痘病毒暴露后出现播散性皮肤病变,病毒载量升高。
  • 西多福韦和抗病毒抗体在湿疹晚期开始治疗仍提供保护。
  • MVA疫苗接种可预防致死性鼠痘病毒暴露,保护依赖CD4+ T细胞。

核心结论

  • 所建立的特应性皮炎与湿疹性牛痘小鼠模型首次模拟人类疾病严重程度。
  • 西多福韦和抗病毒抗体在湿疹晚期开始治疗仍提供保护。
  • MVA疫苗接种可预防致死性鼠痘病毒暴露,保护依赖CD4+ T细胞。

研究设计与样本

  • 研究使用特应性皮炎小鼠模型和鼠痘病毒暴露诱导湿疹性牛痘模型。
  • 评估西多福韦、抗病毒抗体和MVA疫苗接种的保护效果。

主要发现

  • 特应性皮炎小鼠表现为持续性严重皮炎,特征包括皮肤干燥炎症、屏障功能障碍、表皮增生和血清IgE显著升高。
  • 湿疹性小鼠出现增大和播散的皮肤病变,与病毒载量升高相关。
  • 西多福韦和抗病毒抗体在湿疹晚期开始治疗仍提供保护。
  • MVA疫苗接种预防致死性鼠痘病毒暴露,保护依赖CD4+ T细胞,并伴随CD8+细胞毒性T细胞显著活化和体液免疫诱导。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eczema vaccinatum is a severe and occasionally lethal complication of smallpox vaccine, characterized by systemic viral dissemination, distant from the initial inoculation site of the vaccine. A major risk factor for eczema vaccinatum is a background of atopic dermatitis, a chronic, common allergic, relapsing disorder, manifested by dry and inflamed skin, itchy rash, Th2 biased immune response and hypersensitivity to various antigens. Unlike the severe manifestations of eczema vaccinatum in humans, current models present only mild symptoms that limits examination of potential therapeutics for eczema vaccinatum. The atopic dermatitis and eczema vaccinatum models we present here, are the first to simulate the severity of the diseases in humans. Indeed, dermatitic mice display persistent severe dermatitis, characterized by dry and inflamed skin with barrier dysfunction, epidermal hyperplasia and significant elevation of serum IgE. By exposing atopic dermatitis mice to ectromelia virus, we generated eczema vaccinatum that mimic the human disease better than known eczema vaccinatum models. Similarly to humans, eczematous mice displayed enlarged and disseminated skin lesions, which correlated with elevated viral load. Cidofovir and antiviral antibodies conferred protection even when treatment started at a late eczematous stage. Moreover, we are the first to demonstrate that despite a severe background of atopic dermatitis, modified vaccinia Ankara virus (MVA) vaccination protects against lethal ectromelia virus exposure. We finally show that protection by MVA vaccination is dependent on CD4+ T cells and is associated with significant activation of CD8+ cytotoxic T cells and induction of humoral immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Achdout H, Lustig S, Israely T, et al. Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models. Vaccine. 2017. PMID: 28625523. doi:10.1016/j.vaccine.2017.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。